Recursion Pharmaceuticals Inc (RXRX) ニュース

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028 PR Newswire VANCOUVER, BC, Jan. 17, 2025 USA News Group News...

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028 PR Newswire VANCOUVER, BC, Jan. 17, 2025 USA News Group News...

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

Salt Lake City, UT, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to...

Form 144 - Report of proposed sale of securities